Aggressive cutaneous T-cell lymphomas after TNFα blockade

Journal of the American Academy of Dermatology

Volumn 51, Issue 4, 2004, Pages 660-662

  Adams, Amy E ^a,b,c   Zwicker, Jeffrey ^c   Curiel, Clara ^b   Kadin, Marshall E ^c   Falchuk, Kenneth R ^d   Drews, Reed ^c   Kupper, Thomas S ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c Divisions of Hematology Oncology ^*  (United States)

^d Beth Israel Deaconess Medical Center   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; CROHN DISEASE; CUTANEOUS T CELL LYMPHOMA; DEATH; DISEASE COURSE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; T LYMPHOCYTE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CROHN DISEASE; CYCLOPHOSPHAMIDE; CYTOMEGALOVIRUS INFECTIONS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FATAL OUTCOME; FEMALE; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HEART DISEASES; HUMANS; LYMPHOMA, T-CELL; MALE; METHOTREXATE; PREDNISONE; SKIN NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA; VINCRISTINE;

EID: 4644241313     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2004.03.047     Document Type: Article

References (20)

1. L.W. Moreland Inhibitors of tumor necrosis factor for rheumatoid arthritis J Rheumatol 26 1999 7 15
2. W.J. Sandborn, and S.B. Hanauer Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety Inflamm Bowel Dis 5 1999 119 133
3. J. Braun, and J. Sieper Role of novel biological therapies in psoriatic arthritis: effects on joints and skin BioDrugs 17 2003 187 199
4. J. Keane, S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, and W.D. Schwieterman Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent N Engl J Med 345 2001 1098 1104
5. R. Allendoerfer, and G.S. Deepe Jr. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms J Immunol 160 1998 6072 6082
6. S.L. Brown, M.H. Greene, S.K. Gershon, E.T. Edwards, and M.M. Braun Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration Arthritis Rheum 46 2002 3251 3258
7. H.K. Koh, M. Charif, and M.A. Weinstock Epidemiology and clinical manifestations of cutaneous T-cell lymphoma Hematol Oncol Clin North Am 5 1995 943 960
8. D.C. Bodensteiner, and B. Skikne Central nervous system involvement in mycosis fungoides: diagnosis treatment and literature review Cancer 50 1982 1181 1184
9. H.S. Zackheim, C.F. Lebo, P. Wasserstein, N.S. McNutt, E.H. Epstein Jr., and S. Meyler Mycosis fungoides of the mastoid, middle ear, and CNS Arch Derm 119 1983 311 313
10. W. Bushke, A.G. Simons, and H.E. Anders Mycosis fungoides mit Beteiligung des Zentralnervensystems Zentralbl Haut Geschlechtskr 43 1933 723 724
11. M.K. Burns, and K.D. Cooper Cutaneous T-cell lymphoma associated with HIV infection J Am Acad Dermatol 29 1993 394 399
12. B. Kirby, C.M. Owen, R.W. Blewitt, and V.M. Yates Cutaneous T-cell lymphoma developing in a patient on cyclosporin therapy J Am Acad Dermatol 47 2002 S165 S167
13. G. Chen, and D.V. Goeddel TNF-R1 signaling: a beautiful pathway Science 296 2002 1634 1635
14. C. Robert, and T.S. Kupper Inflammatory skin diseases, T cells and immune surveillance N Engl J Med 341 1999 1817 1828
15. R. Horie, and T. Watanabe CD30: expression and function in health and disease Semin Immunol 10 1998 457 470
16. C.S. Duckett, R.W. Gedrich, M.C. Gilfillan, and C.B. Thompson Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2 Mol Cell Biol 17 1997 1535 1542
17. S. Romagnani, G. Del Prete, E. Maggi, M. Chilosi, F. Caligaris-Cappio, and G. Pizzolo CD30 and type 2 T helper (Th2) responses J Leukoc Biol 57 1995 726 730
18. S. Aizawa, H. Nakano, T. Ishida, R. Horie, M. Nagai, and K. Ito Tumor necrosis factor receptor-associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFκB activation J Biol Chem 272 1997 2042 2045
19. S.Y. Lee, S.Y. Lee, G. Kandala, M.L. Liou, H.C. Liou, and Y. Choi CD30/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity Proc Natl Acad Sci USA 93 1996 9699 9703
20. H.J. Gruss, N. Boiani, D.E. Williams, R.J. Armitage, C.A. Smith, and R.G. Goodwin Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell lines Blood 83 1994 2045 2056